A Japanese research team says the experimental drug HUHS1015 is more effective at killing mesothelioma cells and causes fewer side effects than one of the most popular mesothelioma chemotherapy drugs.

It has been reported by Surviving Mesothelioma that doctors in Japan have just released their findings on HUHS1015, an experimental drug they say stopped the growth of Stage IV mesothelioma tumours in laboratory mice better than some current drugs.

Scientists with the Hyogo College of Medicine and the Hyogo University of Health Sciences say HUHS1015, an analogue of the blood pressure drug naftopidil, appears to be more deadly to mesothelioma cells, and cause fewer side effects in laboratory mice, than the popular chemotherapy drugs paclitaxel or cisplatin.

“HUHS1015 effectively suppresses tumor growth in mice inoculated with NCI-H2052, MKN45, or CW2 cells, with a potential similar to or higher than that of currently used anticancer drugs,” writes lead author Tomoyuki Nishizaki.

Writing in the journal Molecules, Dr. Nishizaki and colleagues call HUHS1015, “brilliant hope for cancer therapy.”

“Mesothelioma is one of the most aggressive and most deadly cancers, largely because it only has a marginal response to current cancer drugs,” says Alex Strauss. “We at Surviving Mesothelioma are constantly on the lookout for news of encouraging up-and-coming treatments like HUHS1015.”

HUHS1015 will need to be tested for safety and efficacy in human mesothelioma patients before it can be sold as a drug.

Hopefully these latest developments mean scientists are getting closer to find more effective treatments for mesothelioma, which may in the future lead to a cure.

If you have been affected by mesothelioma, please contact us today on Freephone 0800 294 3035, or talk to us on live chat where we will be happy to answer any questions that you may have.